Chronic myelogenous leukemia initiating cells require Polycomb group protein EZH2

Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myelogenous leukemia (CML) management. Disease eradication, however, is hampered by innate resistance of leukemia initiating cells (LICs) to TKI-induced killing, which also provides the basis for subsequent emergence of TKI-resistant muta...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Discov
Main Authors: Xie, Huafeng, Peng, Cong, Huang, Jialiang, Li, Bin E., Kim, Woojin, Smith, Elenoe C., Fujiwara, Yuko, Qi, Jun, Cheloni, Giulia, Das, Partha P., Nguyen, Minh, Li, Shaoguang, Bradner, James E., Orkin, Stuart H.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5096974/
https://ncbi.nlm.nih.gov/pubmed/27630126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-1439
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares